FR21C1040I1 - Formulations d'anticorps anti-cd20 - Google Patents

Formulations d'anticorps anti-cd20

Info

Publication number: FR21C1040I1
Authority: FR; France
Prior art keywords: antibody formulations; antibody; formulations
Prior art date: 2007-07-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR21C1040C

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novartis AG

Original Assignee

Novartis AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-07-06

Filing date

2021-09-14

Publication date

2021-11-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40228991&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR21C1040(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2021-09-14 Application filed by Novartis AG filed Critical Novartis AG

2021-11-19 Publication of FR21C1040I1 publication Critical patent/FR21C1040I1/fr

Status Active legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Dermatology (AREA)
Molecular Biology (AREA)
Virology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Neurology (AREA)
Pulmonology (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Mycology (AREA)
Microbiology (AREA)
Urology & Nephrology (AREA)
Communicable Diseases (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)

FR21C1040C 2007-07-06 2021-09-14 Formulations d'anticorps anti-cd20 Active FR21C1040I1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US94822007P	2007-07-06	2007-07-06
PCT/US2008/069125 WO2009009407A1 (fr)	2007-07-06	2008-07-03	Formulations d'anticorps

Publications (1)

Publication Number	Publication Date
FR21C1040I1 true FR21C1040I1 (fr)	2021-11-19

Family

ID=40228991

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR21C1040C Active FR21C1040I1 (fr)	2007-07-06	2021-09-14	Formulations d'anticorps anti-cd20

Country Status (38)

Country	Link
US (2)	US20110020328A1 (fr)
EP (2)	EP2170388B1 (fr)
JP (1)	JP5529017B2 (fr)
KR (2)	KR20100038092A (fr)
CN (1)	CN101820912B (fr)
AR (2)	AR067455A1 (fr)
AU (1)	AU2008275278B2 (fr)
BR (2)	BRPI0814003B1 (fr)
CA (1)	CA2692681C (fr)
CL (1)	CL2008001984A1 (fr)
CO (1)	CO6270340A2 (fr)
CR (1)	CR11249A (fr)
CY (3)	CY1118419T1 (fr)
DK (2)	DK2889310T3 (fr)
DO (1)	DOP2010000001A (fr)
EA (1)	EA017994B1 (fr)
ES (2)	ES2663504T3 (fr)
FR (1)	FR21C1040I1 (fr)
HR (2)	HRP20170033T1 (fr)
HU (3)	HUE038501T2 (fr)
IL (1)	IL202950A (fr)
JO (1)	JO3219B1 (fr)
LT (3)	LT2889310T (fr)
MA (1)	MA31471B1 (fr)
MX (1)	MX2010000017A (fr)
MY (1)	MY210424A (fr)
NO (2)	NO2889310T3 (fr)
NZ (1)	NZ582250A (fr)
PE (1)	PE20090738A1 (fr)
PL (2)	PL2889310T3 (fr)
PT (2)	PT2889310T (fr)
SI (2)	SI2170388T1 (fr)
TR (1)	TR201802928T4 (fr)
TW (2)	TWI612060B (fr)
UA (1)	UA107557C2 (fr)
UY (1)	UY31210A1 (fr)
WO (1)	WO2009009407A1 (fr)
ZA (1)	ZA200909107B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20160279239A1 (en)	2011-05-02	2016-09-29	Immunomedics, Inc.	Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US20160355591A1 (en)	2011-05-02	2016-12-08	Immunomedics, Inc.	Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US20100189721A1 (en) *	2007-07-06	2010-07-29	Smithkline Beecham Corporation	Antibody formulations
UA107557C2 (xx) *	2007-07-06	2015-01-26		Композиція антитіла офатумумабу
EP2538973A2 (fr)	2010-02-26	2013-01-02	Novo Nordisk A/S	Compositions stables contenant des anticorps
AU2011223710B2 (en)	2010-03-01	2016-04-14	Bayer Healthcare Llc	Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
US20130136733A1 (en)	2010-05-28	2013-05-30	Novo Nordisk A/S	Stable Multi-Dose Compositions Comprising an Antibody and a Preservative
US20140044727A1 (en) *	2011-04-07	2014-02-13	Glaxosmithkline Llc	Formulations with reduced viscosity
AU2012250872B2 (en)	2011-05-02	2017-07-13	Millennium Pharmaceuticals, Inc.	Formulation for anti-alpha4beta7 antibody
UA116189C2 (uk)	2011-05-02	2018-02-26	Мілленніум Фармасьютікалз, Інк.	КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
CA2831572C (fr)	2011-05-02	2019-11-26	Immunomedics, Inc.	Concentration d'ultrafiltration d'anticorps a allotype selectionne pour une administration de petit volume
UY34105A (es) *	2011-06-03	2012-07-31	Lg Life Sciences Ltd	Formulación líquida estable de etanercept
US9592297B2 (en)	2012-08-31	2017-03-14	Bayer Healthcare Llc	Antibody and protein formulations
ES2899756T3 (es) *	2013-03-12	2022-03-14	Primal Therapies Inc	Composición dental que comprende quelante y base
EP2805730A1 (fr) *	2013-05-21	2014-11-26	Bergen Teknologioverforing AS	Donneurs d'oxyde nitrique pour le traitement du syndrome de fatigue chronique
WO2015162504A1 (fr)	2014-04-23	2015-10-29	Novartis Ag	Nouveau dosage et nouvelles utilisations de l'ofatumumab
WO2016189491A1 (fr) *	2015-05-28	2016-12-01	Glaxosmithkline Intellectual Property Development Limited	Nouvelle formulation
WO2017136433A1 (fr) *	2016-02-03	2017-08-10	Oncobiologics, Inc.	Formulations de tampon pour améliorer la stabilité d'anticorps
SI3497132T1 (sl)	2016-08-15	2020-10-30	Novartis Ag	Režimi in postopki zdravljenja multiple skleroze z uporabo ofatumumaba
WO2018179138A1 (fr) *	2017-03-29	2018-10-04	持田製薬株式会社	Préparation de liquide contenant des anticorps
EP3606964A4 (fr)	2017-04-03	2020-12-09	Immunomedics, Inc.	Administration par voie sous-cutanée de conjugués anticorps-médicament à titre de thérapie anticancéreuse
JOP20190260A1 (ar)	2017-05-02	2019-10-31	Merck Sharp & Dohme	صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
US11845798B2 (en)	2017-05-02	2023-12-19	Merck Sharp & Dohme Llc	Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
US11513046B2 (en) *	2018-02-09	2022-11-29	Championx Usa Inc.	Flowability testing systems and methods
KR20210089215A (ko)	2018-11-07	2021-07-15	머크 샤프 앤드 돔 코포레이션	항-lag3 항체 및 항-pd-1 항체의 공동-제제
TWI874341B (zh)	2018-12-18	2025-03-01	美商健生生物科技公司	產生異二聚體抗體之方法
US20220298253A1 (en)	2019-09-11	2022-09-22	Novartis Ag	Treatment of rms by switching therapy
AU2020347474A1 (en)	2019-09-11	2022-04-07	Novartis Ag	Management of conditions other than multiple sclerosis in ofatumumab-treated patients
CN112675126A (zh) *	2019-10-18	2021-04-20	百奥泰生物制药股份有限公司	抗cd20抗体制剂及其应用
MX2022012600A (es)	2020-04-09	2023-02-15	Novartis Ag	Ofatumumab para el tratamiento de ms mientras se mantiene la igg en el suero.
IL297986A (en)	2020-05-08	2023-01-01	Genmab As	Bispecific antibodies against cd3 and cd20
JP7057954B2 (ja) *	2020-09-03	2022-04-21	国立大学法人大阪大学	改善された保存安定性を有するタンパク質含有液体製剤
US20240228647A1 (en)	2021-04-14	2024-07-11	Novartis Ag	Ofatumumab for treating multiple sclerosis in asian patients
WO2023020802A1 (fr)	2021-08-16	2023-02-23	Novartis Ag	Ofatumumab pour traiter la sclérose en plaques (sep) pédiatrique
KR20230150203A (ko) *	2022-04-20	2023-10-30	주식회사 알토스바이오로직스	오크렐리주맙(Ocrelizumab)을 포함하는 약학적 조성물과 그의 용도
CN116712390B (zh) *	2023-08-04	2023-11-14	上海览屹医药科技有限公司	一种高浓度高稳定性的抗体制剂及其制备方法
WO2025037335A1 (fr) *	2023-08-12	2025-02-20	Dr. Reddy's Laboratories Limited	Formulations d'anticorps anti-cd20

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4816401A (en) *	1985-09-09	1989-03-28	University Of Rochester	Serum free cell culture medium
DE3920358A1 (de)	1989-06-22	1991-01-17	Behringwerke Ag	Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP1136556B1 (fr)	1991-11-25	2005-06-08	Enzon, Inc.	Procédé pour produire de protéines multivalents de fixation de l'antigène
EP0999853B1 (fr) *	1997-06-13	2003-01-02	Genentech, Inc.	Formulation stabilisee renfermant un anticorps
ATE464062T1 (de) *	1999-10-04	2010-04-15	Novartis Vaccines & Diagnostic	Stabilisierte flüssige pharmazeutische zusammensetzung enthaltend tfpi
US7754208B2 (en)	2001-01-17	2010-07-13	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
KR101033196B1 (ko)	2002-02-14	2011-05-09	이뮤노메딕스, 인코오포레이티드	항-ｃｄ20 항체 및 그 융합 단백질 및 이들의 이용방법
EP1478394B1 (fr) *	2002-02-27	2008-07-30	Immunex Corporation	Composition stabilisée comprenant TNFR-Fc et arginine
EP1551875A4 (fr) *	2002-06-21	2006-06-28	Biogen Idec Inc	Preparations tamponnees permettant de concentrer des anticorps et procedes pour les utiliser
PT1558648E (pt) *	2002-10-17	2012-04-23	Genmab As	Anticorpos monoclonais humanos contra cd20
ATE527278T1 (de) *	2002-12-16	2011-10-15	Genmab As	Humane monoklonale antikörper gegen interleukin 8 (il-8)
US8084582B2 (en) *	2003-03-03	2011-12-27	Xencor, Inc.	Optimized anti-CD20 monoclonal antibodies having Fc variants
AR044388A1 (es)	2003-05-20	2005-09-07	Applied Molecular Evolution	Moleculas de union a cd20
US7850962B2 (en)	2004-04-20	2010-12-14	Genmab A/S	Human monoclonal antibodies against CD20
DOP2006000029A (es) *	2005-02-07	2006-08-15	Genentech Inc	Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
WO2006096490A2 (fr) *	2005-03-08	2006-09-14	Pharmacia & Upjohn Company Llc	Compositions d'anticorps anti-madcam
WO2007036745A2 (fr) *	2005-09-30	2007-04-05	Medimmune Limited	Composition comprenant un anticorps anti-interleukine 13
UA107557C2 (xx) *	2007-07-06	2015-01-26		Композиція антитіла офатумумабу
US20100189721A1 (en) *	2007-07-06	2010-07-29	Smithkline Beecham Corporation	Antibody formulations

2008
- 2008-03-07 UA UAA201001165A patent/UA107557C2/ru unknown
- 2008-07-03 LT LTEP15155712.1T patent/LT2889310T/lt unknown
- 2008-07-03 BR BRPI0814003-0A patent/BRPI0814003B1/pt active IP Right Grant
- 2008-07-03 DK DK15155712.1T patent/DK2889310T3/en active
- 2008-07-03 JO JOP/2008/0312A patent/JO3219B1/ar active
- 2008-07-03 EP EP08781323.4A patent/EP2170388B1/fr active Active
- 2008-07-03 BR BR122020026978-2A patent/BR122020026978B1/pt active IP Right Grant
- 2008-07-03 SI SI200831738A patent/SI2170388T1/sl unknown
- 2008-07-03 NZ NZ582250A patent/NZ582250A/en unknown
- 2008-07-03 ES ES15155712.1T patent/ES2663504T3/es active Active
- 2008-07-03 HR HRP20170033TT patent/HRP20170033T1/hr unknown
- 2008-07-03 AU AU2008275278A patent/AU2008275278B2/en active Active
- 2008-07-03 EP EP15155712.1A patent/EP2889310B1/fr active Active
- 2008-07-03 NO NO15155712A patent/NO2889310T3/no unknown
- 2008-07-03 ES ES08781323.4T patent/ES2610821T3/es active Active
- 2008-07-03 LT LTEP08781323.4T patent/LT2170388T/lt unknown
- 2008-07-03 WO PCT/US2008/069125 patent/WO2009009407A1/fr not_active Ceased
- 2008-07-03 JP JP2010516158A patent/JP5529017B2/ja active Active
- 2008-07-03 PT PT151557121T patent/PT2889310T/pt unknown
- 2008-07-03 KR KR1020107000148A patent/KR20100038092A/ko not_active Withdrawn
- 2008-07-03 SI SI200831928T patent/SI2889310T1/en unknown
- 2008-07-03 PL PL15155712T patent/PL2889310T3/pl unknown
- 2008-07-03 KR KR1020157019741A patent/KR101670454B1/ko active Active
- 2008-07-03 MX MX2010000017A patent/MX2010000017A/es active IP Right Grant
- 2008-07-03 CA CA2692681A patent/CA2692681C/fr active Active
- 2008-07-03 DK DK08781323.4T patent/DK2170388T3/en active
- 2008-07-03 EA EA201070105A patent/EA017994B1/ru not_active IP Right Cessation
- 2008-07-03 TR TR2018/02928T patent/TR201802928T4/tr unknown
- 2008-07-03 US US12/667,890 patent/US20110020328A1/en not_active Abandoned
- 2008-07-03 HU HUE15155712A patent/HUE038501T2/hu unknown
- 2008-07-03 PL PL08781323T patent/PL2170388T3/pl unknown
- 2008-07-03 HU HUE08781323A patent/HUE031288T2/hu unknown
- 2008-07-03 CN CN200880105866.1A patent/CN101820912B/zh active Active
- 2008-07-03 MY MYPI2010000010A patent/MY210424A/en unknown
- 2008-07-03 PT PT87813234T patent/PT2170388T/pt unknown
- 2008-07-04 PE PE2008001136A patent/PE20090738A1/es active IP Right Grant
- 2008-07-04 AR ARP080102910A patent/AR067455A1/es unknown
- 2008-07-04 TW TW104128324A patent/TWI612060B/zh active
- 2008-07-04 CL CL2008001984A patent/CL2008001984A1/es unknown
- 2008-07-04 UY UY31210A patent/UY31210A1/es not_active Application Discontinuation
- 2008-07-04 TW TW097125246A patent/TWI515204B/zh active
2009
- 2009-12-21 ZA ZA2009/09107A patent/ZA200909107B/en unknown
- 2009-12-24 IL IL202950A patent/IL202950A/en active IP Right Grant
- 2009-12-30 MA MA32460A patent/MA31471B1/fr unknown
- 2009-12-30 CO CO09149371A patent/CO6270340A2/es active IP Right Grant
2010
- 2010-01-05 DO DO2010000001A patent/DOP2010000001A/es unknown
- 2010-02-02 CR CR11249A patent/CR11249A/es unknown
2015
- 2015-02-19 US US14/625,881 patent/US20150158951A1/en not_active Abandoned
2017
- 2017-01-12 CY CY20171100043T patent/CY1118419T1/el unknown
- 2017-08-29 AR ARP170102392A patent/AR109461A2/es not_active Application Discontinuation
2018
- 2018-03-14 HR HRP20180440TT patent/HRP20180440T1/hr unknown
- 2018-03-20 CY CY20181100325T patent/CY1120047T1/el unknown
2021
- 2021-09-13 NO NO2021036C patent/NO2021036I1/no unknown
- 2021-09-14 CY CY2021027C patent/CY2021027I1/el unknown
- 2021-09-14 FR FR21C1040C patent/FR21C1040I1/fr active Active
- 2021-09-15 HU HUS2100038C patent/HUS2100038I1/hu unknown
- 2021-09-15 LT LTPA2021520C patent/LTPA2021520I1/lt unknown

Also Published As

Publication number	Publication date
CN101820912B (zh)	2014-03-12
HK1141979A1 (zh)	2010-11-26
TR201802928T4 (tr)	2018-03-21
CY1118419T1 (el)	2017-06-28
PL2889310T3 (pl)	2018-06-29
TW201623334A (zh)	2016-07-01
NO2021036I1 (no)	2021-09-13
PE20090738A1 (es)	2009-07-18
SI2889310T1 (en)	2018-04-30
EP2889310B1 (fr)	2017-12-20
EP2170388A1 (fr)	2010-04-07
US20150158951A1 (en)	2015-06-11
LT2889310T (lt)	2018-03-26
US20110020328A1 (en)	2011-01-27
TWI515204B (zh)	2016-01-01
JP2011526880A (ja)	2011-10-20
BRPI0814003A2 (pt)	2015-02-03
CY1120047T1 (el)	2018-12-12
EP2889310A1 (fr)	2015-07-01
CL2008001984A1 (es)	2009-01-09
WO2009009407A1 (fr)	2009-01-15
NZ582250A (en)	2012-04-27
DK2170388T3 (en)	2017-01-16
NO2889310T3 (fr)	2018-05-19
HUE038501T2 (hu)	2018-10-29
PL2170388T3 (pl)	2017-06-30
MY210424A (en)	2025-09-22
CN101820912A (zh)	2010-09-01
IL202950A (en)	2014-05-28
CR11249A (es)	2010-03-08
JP5529017B2 (ja)	2014-06-25
CY2021027I2 (el)	2021-12-31
LTPA2021520I1 (fr)	2021-10-11
MX2010000017A (es)	2010-04-07
IL202950A0 (en)	2011-08-01
SI2170388T1 (sl)	2017-01-31
AU2008275278B2 (en)	2011-04-14
AU2008275278A1 (en)	2009-01-15
EP2170388A4 (fr)	2011-07-06
BR122020026978B1 (pt)	2021-09-28
HK1207652A1 (en)	2016-02-19
CA2692681A1 (fr)	2009-01-15
HRP20170033T1 (hr)	2017-03-24
ES2663504T3 (es)	2018-04-13
DK2889310T3 (en)	2018-03-26
EP2170388B1 (fr)	2016-10-12
DOP2010000001A (es)	2010-01-31
CA2692681C (fr)	2018-12-04
JO3219B1 (ar)	2018-03-08
ZA200909107B (en)	2012-12-27
UY31210A1 (es)	2009-01-30
EA201070105A1 (ru)	2010-08-30
AR067455A1 (es)	2009-10-14
HUS2100038I1 (hu)	2021-10-28
CY2021027I1 (el)	2021-12-31
UA107557C2 (xx)	2015-01-26
MA31471B1 (fr)	2010-06-01
BRPI0814003B1 (pt)	2021-06-15
ES2610821T3 (es)	2017-05-03
PT2170388T (pt)	2017-01-04
KR20100038092A (ko)	2010-04-12
CO6270340A2 (es)	2011-04-20
AR109461A2 (es)	2018-12-12
HRP20180440T1 (hr)	2018-04-20
KR20150088335A (ko)	2015-07-31
LT2170388T (lt)	2017-01-10
HUE031288T2 (hu)	2017-06-28
TW200914466A (en)	2009-04-01
EA017994B1 (ru)	2013-04-30
TWI612060B (zh)	2018-01-21
KR101670454B1 (ko)	2016-10-31
PT2889310T (pt)	2018-03-26

Publication	Publication Date	Title
FR21C1040I1 (fr)	2021-11-19	Formulations d'anticorps anti-cd20
EP2501408A4 (fr)	2014-10-08	Formulations d'anticorps
BRPI0810928A2 (pt)	2019-09-24	"composição farmacêutica"
EP2330193A4 (fr)	2012-07-25	Molécule d'anticorps améliorée
BRPI0913379A2 (pt)	2015-11-24	formulações farmacêuticas sólidas compreendendo bibw 2992
NO20075628L (no)	2007-11-05	Farmasøytiske formuleringer
ITBO20050123A1 (it)	2005-06-06	Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
EP2109625A4 (fr)	2011-06-08	Utilisation de conjugues d'anticorps
EP2076614A4 (fr)	2012-07-04	Anticorps synthetiques
BRPI0814252A2 (pt)	2015-04-14	Formulações de anticorpo
MA29014B1 (fr)	2007-11-01	Formulations d'anticorps
EP2211903A4 (fr)	2011-07-06	Anticorps anti-cll-1
BRPI0810646A2 (pt)	2014-11-04	" compostos farmacêuticos ".
EP1964852A4 (fr)	2010-02-24	Anticorps anti-ilt7
FR2897951B3 (fr)	2008-07-11	Detecteur d'objet
BRPI0716365A2 (pt)	2013-09-24	"artigo odontolàgico"
IL200321A0 (en)	2010-04-29	Stable antibody formulations
EP2102238A4 (fr)	2010-09-01	Anticorps anti-cd44
BRPI0820381A2 (pt)	2015-05-19	Formulações farmacêuticas
BRPI0714539A2 (pt)	2014-02-25	"formas farmacêuticas"
BRPI0819014A2 (pt)	2015-09-08	"descanso de braço"
EP2172483A4 (fr)	2010-08-04	ANTICORPS ANTI-Muc17
EP2011869A4 (fr)	2010-03-17	Nouvel anticorps anti-cd98
EP2004194A4 (fr)	2011-11-23	Formulations d'azoxystrobine
EP2212431A4 (fr)	2011-05-11	Anticorps anti-irem-1